Filing Flows › Pacira BioSciences (PCRX) › Q4 2025
Pacira BioSciences (PCRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Pacira BioSciences (PCRX) reported revenue of $197M for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +10% from the quarter before. Operating margin was 1.2%, net earnings $1.6M (0.8% of revenue).
Pacira BioSciences, Q4 2025: revenue $197M (+5% year over year), operating margin 1.2%, net earnings $1.6M, operating cash flow $43.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $197M | +10% | +5% |
| Operating profit | $2.3M | -63% | -91% |
| Net earnings | $1.6M | -70% | -90% |
| Operating cash flow | $43.7M | -28% | +32% |
| Free cash flow | $43.5M | -24% | +40% |
What changed
Revenue was $196.9M in Q4 2025, up 5% year over year and up 10% from the previous quarter. EXPAREL was the largest line at 79% of revenue.
Operating profit was $2.3M, a 1.2% margin (down 12.0 points year over year). Operating profit fell $22.4M even though revenue rose $9.6M versus a year earlier, so costs grew faster than sales. Total costs grew 20% against revenue growth of 5%. The fastest-growing cost line was Research & development (+57%). Net earnings were $1.6M, down 90% year over year. The tax line was a benefit of $1.1M on pre-tax earnings of $571K.
Operating cash flow was $43.7M (up 32% year over year), 2669% of net earnings. Non-cash charges added back $21.3M of depreciation and amortization and $13.5M of share-based compensation. Working capital and other items added $7.2M. Capital expenditures of $218K left free cash flow of $43.5M.
Questions
What was Pacira BioSciences' revenue in the fourth quarter 2025?
Pacira BioSciences (PCRX) reported revenue of $197M for the fourth quarter 2025 (Q4 2025), +5% from a year earlier and +10% from the quarter before.
Was Pacira BioSciences profitable in the fourth quarter 2025?
Operating profit was $2.3M (1.2% of revenue) and net earnings $1.6M.
Source: Pacira BioSciences 10-K on SEC EDGAR.